[Exploratory Analysis Results from Post-marketing Surveillance Study of Radium-223 in Japanese Patients with Castration-resistant Prostate Cancer and Bone Metastases: Subgroup Analysis by Age].
Makoto HosonoHirotsugu UemuraYoshiyuki KakehiNaoya MasumoriShunji TakahashiYutaka OkayamaToshiyuki SunayaTomoyo HorioSeigo KinuyaPublished in: Kaku igaku. The Japanese journal of nuclear medicine (2021)
Ra-223 therapy seemed tolerable regardless of age in real-world practice in Japan. Especially, there were no new safety concerns of Ra-223 in elderly patients.